Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy

To examine whether serum β2‐microglobulin (β2‐MG) could improve the prediction performance for kidney failure with replacement therapy (KFRT) among patients with diabetic nephropathy (DN).

[1]  F. Hou,et al.  Use of Histologic Parameters to Predict Glomerular Disease Progression: Findings From the China Kidney Biopsy Cohort Study. , 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  A. Rule,et al.  Prognostic Implications of a Morphometric Evaluation for Chronic Changes on All Diagnostic Native Kidney Biopsies , 2022, Journal of the American Society of Nephrology : JASN.

[3]  Gabriel Ștefan,et al.  Adult-onset minimal change disease: the significance of histological chronic changes for clinical presentation and outcome , 2020, Clinical and Experimental Nephrology.

[4]  D. Leaf,et al.  Histopathologic Correlates of Kidney Function: Insights From Nephrectomy Specimens. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  A. Garg,et al.  Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis , 2020, Annals of Internal Medicine.

[6]  M. Woodward,et al.  Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all‐cause mortality in individuals with type 2 diabetes in the ADVANCE trial , 2020, Journal of diabetes.

[7]  Y. Akai,et al.  Renal arteriolar hyalinosis, not intimal thickening in large arteries, is associated with cardiovascular events in people with biopsy‐proven diabetic nephropathy , 2020, Diabetic medicine : a journal of the British Diabetic Association.

[8]  H. Park,et al.  Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus , 2019, PloS one.

[9]  F. Agakov,et al.  Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes , 2018, Diabetologia.

[10]  Anand Srivastava,et al.  The Prognostic Value of Histopathologic Lesions in Native Kidney Biopsy Specimens: Results from the Boston Kidney Biopsy Cohort Study. , 2018, Journal of the American Society of Nephrology : JASN.

[11]  L. Fried,et al.  Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. , 2017, Journal of the American Society of Nephrology : JASN.

[12]  Jai Radhakrishnan,et al.  A proposal for standardized grading of chronic changes in native kidney biopsy specimens. , 2017, Kidney international.

[13]  H. Heerspink,et al.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. , 2017, Journal of the American Society of Nephrology : JASN.

[14]  M. Woodward,et al.  Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England , 2017, PloS one.

[15]  R. Vasan,et al.  Serum β-Trace Protein and β2-Microglobulin as Predictors of ESRD, Mortality, and Cardiovascular Disease in Adults With CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  F. Kronenberg,et al.  Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. , 2016, JAMA.

[17]  F. Agakov,et al.  Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. , 2015, Kidney international.

[18]  R. Vasan,et al.  Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  D. Kyriaki,et al.  The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatment , 2015, Journal of Diabetes & Metabolic Disorders.

[20]  J. Skupień,et al.  Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria , 2013, Diabetes Care.

[21]  K. Ohashi,et al.  Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  H. Asashima,et al.  Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still’s disease , 2013, Clinical Rheumatology.

[23]  Z. Massy,et al.  Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. , 2012, Kidney international.

[24]  Yu Sun,et al.  Neonatal Fc receptor stimulation induces ubiquitin c-terminal hydrolase-1 overexpression in podocytes through activation of p38 mitogen-activated protein kinase. , 2012, Human pathology.

[25]  B. Astor,et al.  Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[27]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[28]  Jai Radhakrishnan,et al.  Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[29]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  M. Inaba,et al.  Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[32]  I. Heilberg,et al.  Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[33]  Emil R. Unanue,et al.  Podocytes use FcRn to clear IgG from the glomerular basement membrane , 2008, Proceedings of the National Academy of Sciences.

[34]  N. Fernández,et al.  Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children , 2007, Critical care.

[35]  S. Ito,et al.  Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease , 2007, Clinical and Experimental Nephrology.

[36]  E. Lewis,et al.  Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. , 2005, Journal of the American Society of Nephrology : JASN.

[37]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[38]  R. Atkins,et al.  The Role of p38α Mitogen-Activated Protein Kinase Activation in Renal Fibrosis , 2004 .

[39]  W. Hunziker,et al.  beta(2)-Microglobulin is important for cell surface expression and pH-dependent IgG binding of human FcRn. , 2002, Journal of cell science.

[40]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[41]  J. Haymann,et al.  Characterization and localization of the neonatal Fc receptor in adult human kidney. , 2000, Journal of the American Society of Nephrology : JASN.

[42]  H. Seo,et al.  Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. , 1994, The Journal of clinical investigation.

[43]  M. Kondo,et al.  Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. , 1991, Kidney international.

[44]  E. de Menis,et al.  Increased serum beta 2-microglobulin concentrations in hyperthyroid states. , 1991, Journal of clinical pathology.

[45]  L. W. Statius van Eps,et al.  β2-microglobulin: Its significance in the evaluation of renal function , 1987 .

[46]  J P Kriss,et al.  Limitations of creatinine as a filtration marker in glomerulopathic patients. , 1985, Kidney international.

[47]  G. Karvountzis,et al.  Serum β2 microglobulin in malignant lymphoproliferative disorders , 1985 .

[48]  I. Berggård,et al.  Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids. , 1968, The Journal of biological chemistry.

[49]  T. Nishino,et al.  Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  N. Perico,et al.  Timed urine collections are not needed to measure urine protein excretion in clinical practice. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  William Clark,et al.  Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. , 2006, Journal of the American Society of Nephrology : JASN.